In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...